Drugs / Oregovomab
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03162562 | May 2017 → Nov 2020 | ovarian carcinoma, uterine adnexa cancer | CanariaBio Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04938583 | Mar 2021 → Oct 2025 overdue | ovarian carcinoma, uterine adnexa cancer | CanariaBio Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04620954 | Oct 2020 → Jul 2022 | malignant epithelial tumor of ovary | National Cancer Centre, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT03100006 | Feb 2017 → Jun 2019 | ovarian epithelial tumor | National Cancer Centre, Singapore | Terminated | No outcome recorded |
| Phase 1/2 | NCT00034138 | Mar 2002 → Dec 2007 | ovarian neoplasm | Unither Pharmaceuticals | Terminated | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05605535 | Feb 2023 → Oct 2026 expected | fallopian tube neoplasm, ovarian serous adenocarcinoma, peritoneal carcinoma | CanariaBio Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05335993 | Jul 2022 → Dec 2026 expected | fallopian tube cancer, ovarian adenocarcinoma, peritoneum cancer | CanariaBio Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05407584 | Jul 2022 → May 2024 | — | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT01959672 | Sep 2013 → Apr 2018 | pancreatic adenocarcinoma | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT01616303 | Jun 2012 → Jun 2015 | ovarian cancer | Quest PharmaTech Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00086632 | Jul 2004 → Dec 2007 | ovarian cancer | Unither Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00034372 | Sep 2000 → Dec 2007 | ovarian neoplasm | Unither Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00004064 | Nov 1998 → ? | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | AltaRex | Unknown | No outcome recorded |
| Phase 2 | NCT00003634 | Apr 1998 → ? | fallopian tube cancer, ovarian cancer, peritoneum cancer | AltaRex | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04498117 | Aug 2020 → Dec 2026 expected | fallopian tube serous adenocarcinoma, ovarian serous adenocarcinoma, peritoneal carcinoma | CanariaBio Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00050375 | Dec 2002 → Dec 2007 | ovarian cancer | Unither Pharmaceuticals | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00551265 | Oct 2007 → Jan 2009 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Gynecologic Oncology Group | Withdrawn | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oregovomab | “Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following PLD over approximately 20 (acceptable range 15-30) minutes for a total...” NCT05407584 ↗ |
| Known as | B43.13 | “Arm I: Patients receive OvaRex monoclonal antibody B43.13 IV on day 0.” NCT00003634 ↗ |
| Known as | MAb-B43.13 | “An experimental treatment with OvaRex® MAb-B43.13 (oregovomab), called immunotherapy is being tested in ovarian cancer patients.” NCT00086632 ↗ |
| Known as | Oregovamab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107917 ↗ |
| Known as | OvaRex | “An experimental treatment with OvaRex® MAb-B43.13 (oregovomab), called immunotherapy is being tested in ovarian cancer patients.” NCT00086632 ↗1“Arm I: Patients receive OvaRex monoclonal antibody B43.13 IV on day 0.” NCT00003634 ↗ |
| Action | Inhibit | “Monoclonal antibodies, such as oregovomab, can block tumor growth in different ways by targeting certain cells.” NCT01959672 ↗ |
| Modality | Monoclonal antibody | “OvaRex monoclonal antibody B43.13” NCT00003634 ↗ |
| Route | Intravenous | “Patients receive OvaRex monoclonal antibody B43.13 IV on day 0.” NCT00003634 ↗ |
| Target | MUC16 | “Mucin-16 other” CHEMBL2107917 ↗ |